TU + NET-EN
Alternative Name: Testosterone undecanoate (TU) + norethisterone enanthate (NET-EN)
Description: An intramuscular injections of 200-mg norethisterone enanthate (NET-EN) combined with 1000-mg testosterone undecanoate (TU), administered every 8 weeks. Mechanism of action is suppression of spermatogenesis.
Product Details
Regimen:
Dose: 200 mg NET-EN, 1000mg TU
Active Pharmaceutical Ingredient (API):
Status Details
Developer: , ,
Status Details: - A global Phase IIb clinical trial was discontinued in April 2011 after a WHO review panel determined that the risks of possible side effects might outweigh the potential benefits to male participants.
- A global Phase IIb clinical trial was discontinued in April 2011 after a WHO review panel determined that the risks of possible side effects might outweigh the potential benefits to male participants.
Additional Information
References: Kamischke A, et al. (2001) Intramuscular testosterone undecanoate and norethisterone enanthate in a clinical trial for male contraception. J Clin Endocrinol Metab 86(1): 303-9.
Behre HM, et al. (2016) Efficacy and Safety of an Injectable Combination Hormonal Contraceptive for Men. J Clin Endocrinol Metab.
Kamischke A, et al. (2001) Intramuscular testosterone undecanoate and norethisterone enanthate in a clinical trial for male contraception. J Clin Endocrinol Metab 86(1): 303-9.
Behre HM, et al. (2016) Efficacy and Safety of an Injectable Combination Hormonal Contraceptive for Men. J Clin Endocrinol Metab.